Proposed addiction treatment blocks environment-triggered craving

March 06, 2001

Treatment may help diminish addicts' tendency to relapse Upton, NY -- Anecdotal reports suggest that addicts crave drugs when they visit places where they've routinely used drugs. Now, a new study funded by the U.S. Department of Energy and conducted at Brookhaven National Laboratory shows that, in animals, such environmental cues trigger measurable increases in dopamine, a brain chemical closely linked with addiction. Even more important, lab scientists demonstrate that a therapeutic agent they've been studying as a potential treatment for addiction completely blocks this environmentally triggered increase in dopamine.

These findings extend the potential value of this therapeutic agent, known as GVG (or gamma-vinyl GABA), which the Brookhaven team has previously shown to be effective at blocking the neurochemical and behavioral effects of addictive drugs such as cocaine, nicotine, methamphetamine, and alcohol.

"This is the first therapeutic agent that successfully combats three major components of drug addiction -- the neurochemical and behavioral effects of the drug itself and the neurochemical changes triggered by drug-related environmental cues," says Stephen Dewey, the Brookhaven neuroanatomist who led the study. This research will be published in the March 7, 2001 issue of the European Journal of Pharmacology.

All addictive drugs elevate dopamine levels in the parts of the brain associated with reward and reinforcement. It is thought that this reinforcing effect is the primary biochemical explanation for addiction. GVG indirectly depletes dopamine. It works by inhibiting an enzyme that normally breaks down gamma amino butyric acid (GABA), a dopamine-modulating enzyme. The resulting excess GABA breaks down the excess dopamine.

Previously, Dewey's group has shown that GVG can block drug-triggered increases in dopamine and drug-craving behavior in animals. But they wondered whether environmental cues, such as being in a drug-related environment, might trigger increases in dopamine in the absence of the drug. Both would provide a biochemical mechanism for craving, and another potential target for treatment by GVG.

To find out, they measured brain dopamine levels in laboratory rats that had been trained to expect cocaine in a given environment and rats that received no treatment and no cocaine (the controls). When the animals trained to expect cocaine later entered the "drug" environment, their dopamine levels increased by about 25 percent as compared to the controls, even when no cocaine was given. If cocaine-trained animals were first given GVG before entering the drug environment, however, their dopamine levels remained normal.

This demonstrates that environmental cues that lead to drug craving do trigger increases in dopamine, and that GVG can block this effect in addition to the direct biochemical effects of the drug. "No other drug has been tested as extensively for substance abuse treatment as GVG," says Dewey. "And no other drug has been tested for substance abuse treatment using these simultaneous biochemical and behavioral tests."
Dewey's proposed GVG treatment protocol was recently awarded U.S. Patent No. 6,057,368, based on previous animal studies. But before it can be implemented in this country, GVG must undergo clinical testing to ensure its safety and effectiveness for human use. Manufactured by the French company Aventis, GVG (also known as Sabril® or vigabatrin) is currently used for the treatment of epilepsy in children in more than 65 other countries, but it is not approved for use in the United States.

As noted, the current study was funded by the U.S. Department of Energy joined by the National Institute of Mental Health, part of the National Institutes of Health. It was done in collaboration with researchers from St. John's University, Albert Einstein College of Medicine, New York University School of Medicine, and Chirotech Technology Ltd.

For information on Brookhaven's previous GVG studies, go to:

The U.S. Department of Energy's Brookhaven National Laboratory creates and operates major facilities available to university, industrial and government personnel for basic and applied research in the physical, biomedical and environmental sciences and in selected energy technologies. The Laboratory is operated by Brookhaven Science Associates, a not-for-profit research management company, under contract with the U.S. Department of Energy.

Note to local editors: Stephen Dewey lives in Manorville, New York.

DOE/Brookhaven National Laboratory

Related Cocaine Articles from Brightsurf:

Sleep-deprived mice find cocaine more rewarding
Sleep deprivation may pave the way to cocaine addiction. Too-little sleep can increase the rewarding properties of cocaine, according to new research in mice published in eNeuro.

Nucleus accumbens recruited by cocaine, sugar are different
In a study using genetically modified mice, a University of Wyoming faculty member found that the nucleus accumbens recruited by cocaine use are largely distinct from nucleus accumbens recruited by sucrose, or table sugar.

Astrocytes build synapses after cocaine use in mice
Drugs of abuse, like cocaine, are so addictive due in part to their cellular interaction, creating strong cellular memories in the brain that promote compulsive behaviors.

Of all professions, construction workers most likely to use opioids and cocaine
Construction workers are more likely to use drugs than workers in other professions, finds a study by the Center for Drug Use and HIV/HCV Research (CDUHR) at NYU College of Global Public Health.

Chronic cocaine use modifies gene expression
Chronic cocaine use changes gene expression in the hippocampus, according to research in mice recently published in JNeurosci.

Blocking dopamine weakens effects of cocaine
Blocking dopamine receptors in different regions of the amygdala reduces drug seeking and taking behavior with varying longevity, according to research in rats published in eNeuro.

Born to run: just not on cocaine
A study finds a surprising response to cocaine in a novel strain of mutant mice -- they failed to show hyperactivity seen in normal mice when given cocaine and didn't run around.

Cocaine adulterant may cause brain damage
People who regularly take cocaine cut with the animal anti-worming agent levamisole demonstrate impaired cognitive performance and a thinned prefrontal cortex.

Setting affects pleasure of heroin and cocaine
Drug users show substance-specific differences in the rewarding effects of heroin versus cocaine depending on where they use the drugs, according to a study published in JNeurosci.

One in 10 people have traces of cocaine or heroin on their fingerprints
Scientists have found that drugs are now so prevalent that 13 percent of those taking part in a test were found to have traces of class A drugs on their fingerprints -- despite never using them.

Read More: Cocaine News and Cocaine Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to